Shilpa Medicare Q1 FY27: Profit Attributable Doubles YoY

Board clears June-quarter numbers

Shilpa Medicare Limited said its board of directors met on August 5, 2026 to approve unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and then taken up by the board. The company also said its statutory auditors issued an unmodified opinion after a limited review.

Some parts of the information circulating around the meeting were flagged as coming from an unverified source alert, including the immediate quarterly profit headline. However, the same dataset also contains detailed line items in lakhs for standalone and consolidated performance, along with corporate action dates and an overseas strategic investment approval.

Unverified alert vs published profit figures

An unverified source alert claimed consolidated net profit of about ₹100 crore for the June 2026 quarter, compared with about ₹47 crore in the year-ago quarter. In the detailed numbers shared alongside, consolidated net profit attributable to owners for the quarter was stated at ₹100.88 crore (₹10,088 lakh), up from ₹46.88 crore (₹4,688 lakh) year-on-year.

On the standalone side, the company reported net profit of ₹64.92 crore (₹6,492 lakh) versus ₹18.71 crore (₹1,871 lakh) in the comparable quarter last year. Total standalone income for the quarter was stated at ₹198.60 crore (₹19,860 lakh) versus ₹106.48 crore (₹10,648 lakh) a year ago. Total consolidated income for the quarter was stated at ₹468.91 crore (₹46,891 lakh) versus ₹327.85 crore (₹32,785 lakh) in the same quarter last year.

How the quarter compares with earlier disclosed Q1 figures

The article dataset also contains a separate Q1 performance snapshot stating: total revenue of ₹328 crore versus ₹302 crore in Q1 FY25, EBITDA of ₹98 crore versus ₹83 crore, and PAT of ₹47 crore versus ₹14 crore. Another line item in the dataset states that for the prior-year quarter (Q1 FY26), consolidated net profit was ₹46.89 crore on revenue of ₹321.46 crore.

Because the labels in the provided material mix “Q1 FY26” and “quarter ended June 30, 2026”, this story sticks to the quarter-end date (June 30, 2026) and reports figures exactly as presented in the dataset. Where multiple revenue and profit numbers are presented for a similar period, they are shown as separate disclosures within the same source bundle rather than being merged.

Key figures mentioned for the June 2026 quarter

The company’s June-quarter performance is described in multiple places within the dataset, including a quarterly overview that highlights a revenue figure of ₹439 crore and EBITDA of ₹121 crore, along with margins. Separately, the company’s consolidated total income for the June 2026 quarter is stated at ₹468.91 crore.

The quarterly overview also notes a gross margin of 68% for the quarter and an EBITDA margin of 28%. Adjusted PAT for the quarter is listed at ₹87 crore, with an increase of about 135% year-on-year in that summary. These figures are presented as part of a broader financial overview and are not reconciled within the text.

FY26 full-year backdrop: growth and profitability jump

For the full year FY26, the dataset states consolidated revenue of ₹1,538.87 crore, representing 19.62% year-on-year growth. Consolidated net profit for FY26 is stated at ₹243.33 crore, compared with ₹78.29 crore in the previous fiscal year. A separate full-year snapshot in the same dataset states annual revenue of ₹1,549 crore (up 18% year-on-year) and annual EBITDA of ₹445 crore (up 30% year-on-year).

The FY26 dataset also flags higher leverage and investment: net debt rose to ₹613 crore from ₹550 crore in the previous year, and FY26 capital expenditure was ₹361 crore, primarily funded through internal funds. Adjusted ROCE is stated to have improved to 11.4% in FY26 (with the earlier-year figure not clearly legible in the provided material).

Segment notes: API, formulations and biologics

The dataset references growth drivers across APIs and biologics, including management commentary that June-quarter revenues were driven by these verticals. One call transcript excerpt states quarterly revenue at ₹328 crore and highlights a gross margin of 76% for that quarter, up 700 basis points year-on-year, supported by product mix and licensing income.

In another excerpt, formulation revenues for the quarter are stated at ₹98 crore. A separate financial overview notes that biologics revenue nearly doubled year-on-year for the year, though the absolute biologics revenue number is not legible in the supplied text. The dataset also references strategic expansions in the European biologics market as part of the broader context.

Corporate actions: dividend record date and AGM schedule

Alongside the results approval, the board set September 4, 2026 as the record date for the final dividend for FY 2025-26. The company also scheduled its 39th Annual General Meeting (AGM) for September 11, 2026. These dates are relevant for shareholders tracking eligibility for the final dividend and participation in corporate governance events.

Strategic investment: up to EUR 7 million in Gate2Brain

Shilpa Medicare’s board also approved a strategic investment of up to EUR 7 million in Gate2Brain. The investment is to be made through its wholly owned subsidiary, Shilpa Biocare Private Limited. The dataset does not provide further deal terms, valuation, or timelines beyond the maximum investment amount and the approval.

Key data table

Market impact and what investors typically track next

The immediate market read-through for investors is usually centered on profit quality, income growth, and margins, but this dataset contains multiple revenue and margin snapshots for similar periods. What is consistent across the material is a sharp year-on-year rise in profit attributable to owners to about ₹101 crore for the June 2026 quarter, and the company’s emphasis on API, formulations, and biologics as growth drivers.

The dividend record date and AGM timeline are clear next milestones for shareholders. Beyond that, the Gate2Brain investment approval is a concrete strategic action, although the dataset does not provide operational or financial guidance on how it may contribute to Shilpa Medicare’s earnings.

Conclusion

Shilpa Medicare’s board approved unaudited June 2026 quarter results on August 5, 2026, with consolidated profit attributable to owners stated at ₹100.88 crore, up from ₹46.88 crore year-on-year. The company also fixed September 4, 2026 as the record date for the final dividend for FY 2025-26 and scheduled the 39th AGM for September 11, 2026. Separately, the board cleared an investment of up to EUR 7 million in Gate2Brain via Shilpa Biocare. The next confirmed events on the calendar are the record date and AGM, while further details on the Gate2Brain investment would likely come through subsequent company communication.